Literature DB >> 28552471

Emerging extended-spectrum β-lactamase-producing Klebsiella pneumoniae causing community-onset urinary tract infections: a case-control-control study.

Lucía Boix-Palop1, Mariona Xercavins2, Cristina Badía3, Meritxell Obradors3, Montserrat Riera4, Núria Freixas4, Josefa Pérez2, Mónica Rodríguez-Carballeira3, Javier Garau5, Esther Calbo6.   

Abstract

The aim of this study was to determine the epidemiology and risk factors associated with community-onset urinary tract infections (CO-UTIs) due to extended-spectrum β-lactamase-producing Klebsiella pneumoniae (ESBL-Kp). A cohort study including all consecutive patients with K. pneumoniae CO-UTI identified from January 2010 to December 2014 was conducted. Patients with CO-UTI due to ESBL-Kp were then included as cases in a retrospective case-control-control study; controls were outpatients with CO-UTI caused by non-ESBL-producing Escherichia coli and K. pneumoniae (non-ESBL-Ec and non-ESBL-Kp, respectively). Each control was matched in a 2:1 ratio according to patient age, sex and year of isolation. Genotyping confirming ESBL was performed by multiplex PCR and sequencing. The prevalence of ESBL-Kp CO-UTIs, calculated among all K. pneumoniae CO-UTIs, increased from 2.4% in 2010 to 10.3% in 2014 (P = 0.01). Among cases, 63.8% were truly community-acquired, and CTX-M-15 was the predominant β-lactamase enzyme type (79.3%). A total of 83 cases and 319 controls were studied. Being a nursing home resident [odds ratio (OR) = 8.8, 95% confidence interval (CI) 2.6-29.4] and previous cephalosporin use (OR = 4.01, 95% CI 1.8-9.2) were risk factors independently associated with CO-UTI due to ESBL-Kp. In conclusion, the prevalence of CO-UTIs due to ESBL-Kp is increasing. In most cases, ESBL-Kp CO-UTIs are community-acquired and produce CTX-M-15 β-lactamase. Exposure to cephalosporins and being a nursing home resident were risk factors associated with ESBL-Kp CO-UTIs. CTX-M-15-producing K. pneumoniae isolates are emerging in the community.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  CTX-M-15; Community-onset; Extended-spectrum β-lactamase; Klebsiella pneumoniae; Urinary tract infection

Mesh:

Substances:

Year:  2017        PMID: 28552471     DOI: 10.1016/j.ijantimicag.2017.03.009

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Spinal epidural abscess caused by a community acquired extended spectrum beta lactamase producing Klebsiella pneumonia.

Authors:  Vinh Dang; Aarthi Rajkumar
Journal:  IDCases       Date:  2018-08-08

2.  Efficacy of a Postprescription Review of Broad-Spectrum Antimicrobial Agents With Feedback: A 4-Year Experience of Antimicrobial Stewardship at a Tertiary Care Center.

Authors:  Hitoshi Honda; Shutaro Murakami; Yasuaki Tagashira; Yuki Uenoyama; Kaoru Goto; Akane Takamatsu; Shinya Hasegawa; Yasuharu Tokuda
Journal:  Open Forum Infect Dis       Date:  2018-11-22       Impact factor: 3.835

3.  High clonal diversity of ESBL-producing Klebsiella pneumoniae isolates from clinical samples in a non-outbreak situation. A cohort study.

Authors:  Mariona Xercavins; Elena Jiménez; Emma Padilla; Montserrat Riera; Núria Freixas; Lucia Boix-Palop; Josefa Pérez; Esther Calbo
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-03       Impact factor: 4.887

4.  From Pathophysiological Hypotheses to Case-Control Study Design: Resistance from Antibiotic Exposure in Community-Onset Infections.

Authors:  Salam Abbara; Didier Guillemot; Christian Brun-Buisson; Laurence Watier
Journal:  Antibiotics (Basel)       Date:  2022-02-04

5.  Clinical and Economic Impact of Community-Onset Urinary Tract Infections Caused by ESBL-Producing Klebsiella pneumoniae Requiring Hospitalization in Spain: An Observational Cohort Study.

Authors:  Dawid Rozenkiewicz; Erika Esteve-Palau; Mar Arenas-Miras; Santiago Grau; Xavier Duran; Luisa Sorlí; María Milagro Montero; Juan P Horcajada
Journal:  Antibiotics (Basel)       Date:  2021-05-15

6.  Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases.

Authors:  Cassandra L Chatwin; Jodie C Hamrick; Robert E L Trout; Cullen L Myers; Susan M Cusick; William J Weiss; Mark E Pulse; Luigi Xerri; Christopher J Burns; Gregory Moeck; Denis M Daigle; Kaitlyn John; Tsuyoshi Uehara; Daniel C Pevear
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

7.  Antibiotic prescriptions and risk factors for antimicrobial resistance in patients hospitalized with urinary tract infection: a matched case-control study using the French health insurance database (SNDS).

Authors:  Marion Opatowski; Christian Brun-Buisson; Mehdi Touat; Jérôme Salomon; Didier Guillemot; Philippe Tuppin; Laurence Watier
Journal:  BMC Infect Dis       Date:  2021-06-14       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.